Nubytide - Cenna Biosciences
Latest Information Update: 12 Jan 2024
Price :
$50 *
At a glance
- Originator Cenna Biosciences
- Class Antidementias; Peptides
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 04 Jan 2024 Cenna Biosciences announces intention to submit IND for Alzheimer's disease in 2024 (Cenna Biosciences pipeline, January 2024)
- 03 Jan 2024 Cenna Biosciences has patent protection for Nubytide in the World (Cenna Biosciences pipeline, January 2024)
- 03 Jan 2024 Cenna Biosciences has patent protection for Nubytide in USA (Cenna Biosciences pipeline, January 2024)